PEDIATRICS Vol. 99 No. 4 April 1997, pp. 645-650 (doi:10.1542/peds.99.4.645)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Committee on Fetus and Newborn,
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Committee on Fetus and Newborn,
Related Collections
Right arrow Infectious Disease & Immunity

PEDIATRICS Vol. 99 No. 4 April 1997, pp. 645-650

AMERICAN ACADEMY OF PEDIATRICS:
Respiratory Syncytial Virus Immune Globulin Intravenous: Indications for Use

Committee on Infectious Diseases and Committee on Fetus and Newborn

Respiratory syncytial virus immune globulin intravenous (RSV-IGIV) has been approved by the Food and Drug Administration for use in the prevention of severe RSV infections in infants and children younger than 24 months with bronchopulmonary dysplasia or a history of premature birth (<= 35 weeks of gestation). RSV-IGIV administered monthly during the RSV season resulted in a 41% to 65% reduction in hospitalization rates in two clinical trials; however, RSV-IGIV is costly, and intravenous administration can be logistically demanding. RSV-IGIV should be considered for infants with bronchopulmonary dysplasia who are receiving or have received oxygen therapy in the past 6 months. Infants with gestational ages of 32 weeks or less may also benefit clinically from RSV-IGIV prophylaxis. Immunization with measles-containing vaccines should be delayed for 9 months after the last dose of RSV-IGIV, but no changes need to be made for all other routinely administered vaccines. RSV-IGIV has not been approved for use in children with congenital heart disease, and available data indicate that RSV-IGIV should not be administered to children with cyanotic congenital heart disease because of safety concerns.


The following policy statements are a revision:

Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV

Pediatrics 102: 1211-1216. [Full Text]

Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections

Pediatrics 112: 1442-1446. [Full Text]

Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections
, , and
Pediatrics 112: 1447-1452. [Full Text]



This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
A. Mejias, S. Chavez-Bueno, A. M. Rios, J. Saavedra-Lozano, M. Fonseca Aten, J. Hatfield, P. Kapur, A. M. Gomez, H. S. Jafri, and O. Ramilo
Anti-Respiratory Syncytial Virus (RSV) Neutralizing Antibody Decreases Lung Inflammation, Airway Obstruction, and Airway Hyperresponsiveness in a Murine RSV Model
Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1811 - 1822.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
Committee on Infectious Diseases and Committee on
Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections
Pediatrics, December 1, 2003; 112(6): 1442 - 1446.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
H. C. Meissner, S. S. Long, and Committee on Infectious Diseases, and Committee on
Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections
Pediatrics, December 1, 2003; 112(6): 1447 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
M. A. Keller and E. R. Stiehm
Passive Immunity in Prevention and Treatment of Infectious Diseases
Clin. Microbiol. Rev., October 1, 2000; 13(4): 602 - 614.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
M. Thomas, A. Bedford-Russell, and M. Sharland
Hospitalisation for RSV infection in ex-preterm infants---implications for use of RSV immune globulin
Arch. Dis. Child., August 1, 2000; 83(2): 122 - 127.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. Joffe, G. J. Escobar, S. B. Black, M. A. Armstrong, and T. A. Lieu
Rehospitalization for Respiratory Syncytial Virus Among Premature Infants
Pediatrics, October 1, 1999; 104(4): 894 - 899.
[Abstract] [Full Text]

Home page
 Arch Pediatr Adolesc MedHome page
G. J. Redding, S. Braun, and D. Mayock
Impact of Respiratory Syncytial Virus Immune Globulin in 1996-1997: A Local Controlled Comparison
Arch Pediatr Adolesc Med, May 1, 1999; 153(5): 503 - 507.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Microbiol. Rev.Home page
J. B. Domachowske and H. F. Rosenberg
Respiratory Syncytial Virus Infection: Immune Response, Immunopathogenesis, and Treatment
Clin. Microbiol. Rev., April 1, 1999; 12(2): 298 - 309.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
F. W. MOLER and S. E. OHMIT
Severity Of Illness Models For Respiratory Syncytial Virus-Associated Hospitalization
Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): 1234 - 1240.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
Committee on Infectious Diseases and Committee on
Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIV
Pediatrics, November 1, 1998; 102(5): 1211 - 1216.
[Abstract] [Full Text]

Home page
 PediatricsHome page
The IMpact-RSV Study Group
Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants
Pediatrics, September 1, 1998; 102(3): 531 - 537.
[Abstract] [Full Text] [PDF]

Home page
 Arch Pediatr Adolesc MedHome page
J. M. Robbins, J. M. Tilford, R. F. Jacobs, J. G. Wheeler, S. R. Gillaspy, and G. E. Schutze
A Number-Needed-to-Treat Analysis of the Use of Respiratory Syncytial Virus Immune Globulin to Prevent Hospitalization
Arch Pediatr Adolesc Med, April 1, 1998; 152(4): 358 - 366.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. A. Nachman, M. Navaie-Waliser, and M. Z. Qureshi
Rehospitalization With Respiratory Syncytial Virus After Neonatal Intensive Care Unit Discharge: A 3-Year Follow-up
Pediatrics, December 1, 1997; 100(6): e8 - e8.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
W. Oh and G. Merenstein
Fourth Edition of the Guidelines for Perinatal Care: Summary of Changes
Pediatrics, December 1, 1997; 100(6): 1021 - 1022.
[Full Text] [PDF]